<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="99707">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01806597</url>
  </required_header>
  <id_info>
    <org_study_id>CAIN457A2312</org_study_id>
    <secondary_id>2012-005412-25</secondary_id>
    <nct_id>NCT01806597</nct_id>
  </id_info>
  <brief_title>Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis</brief_title>
  <acronym>GESTURE</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Demonstrate the Efficacy at 16 Weeks of Secukinumab 150 and 300 mg s.c. and to Assess Safety, Tolerability and Long-term Efficacy up to 132 Weeks in Subjects With Moderate to Severe Palmoplantar Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose of the study is to demonstrate the efficacy of secukinumab versus placebo on
      palmoplantar psoriasis and to assess the long term efficacy, safety and tolerability of
      secukinumab.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 19, 2013</start_date>
  <completion_date type="Actual">November 2, 2016</completion_date>
  <primary_completion_date type="Actual">November 2, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy:palmoplantar Investigator Global Assessmnet (ppIGA) response after 16 weeks of treatment. Each of the treatment groups will be compared to placebo.</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
    <description>Primary endpoint is the palmoplantar Investigator's Global Assessment (ppIGA) response after 16 weeks of treatment. To be considered a ppIGA responder at Week 16, a subject must have ppIGA of 0 or 1 at Week 16 and a reduction of at least 2 points on the ppIGA scale from baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy: palmoplantar Investigator Global Assessment (ppIGA) response over time up to Week 16, and over time up to Week 80 or Week 132</measure>
    <time_frame>16 weeks, 132 weeks</time_frame>
    <description>The ppIGA scores signs of plaque psoriasis on the palms and soles. A subject is considered ppIGA responder at specific points in time if the ppIGA score at the time of assessment is 0 or 1 AND if at that time, there is a reduction from baseline of at least 2 points on the ppIGA scale. Response to treatment will be assessed in each secukinumab group over time up to Week 16 in comparison with placebo, and over time until Week 132.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: palmoplantar Psoriasis Area and Severity Index (ppPASI) over time up to Week 16 compared to placebo, and over time up to Week 132</measure>
    <time_frame>16 weeks, 132 weeks</time_frame>
    <description>The ppPASI score evaluates erythema, induration and desquamation, as well as the affected area of palms and soles. Percentage change in ppPASI score from baseline will be assessed in each secukinumab group over time up to Week 16 in comparison with placebo, and over time up to Week 132.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects in treatment groups 150mg and 300mg with adverse events, safety labs, ECG, and vital signs as a measure of safety and tolerability</measure>
    <time_frame>Baseline, up to 140 weeks</time_frame>
    <description>Adverse events, safety labs, ECG and vital signs will be used to assess safety and tolerability of the study treatment in patients who took at least one dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of subjects who develop immunogenicity against secukinumab</measure>
    <time_frame>Baseline, 32 weeks, 80 weeks, 132 weeks, 88 weeks or 140 weeks</time_frame>
    <description>Overall statistics will be used to assess the immunogenicity of secukinumab. Patients who discontinue treatment after Week 80 will have the last immunogenicity test performed at Week 88, all other patients - at Week 140.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">205</enrollment>
  <condition>Moderate to Severe Palmoplantar Psoriasis</condition>
  <arm_group>
    <arm_group_label>secukinumab 150mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>201 subjects will be randomized in a 1:1:1 ratio to secukinumab either 150 mg or 300 mg, or placebo. Subjects assigned to secukinumab 150 mg will be dosed weekly for the first five weeks, then every four weeks up to and including Week 128. To maintain blinding, subjects will receive additional placebo injections at Weeks 17, 18 and 19. All doses of study treatment are administered by sub-cutaneous injections.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>secukinumab 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>201 subjects will be randomized in a 1:1:1 ratio to secukinumab either 150 mg or 300 mg, or placebo. Subjects assigned to secukinumab 300 mg will be dosed weekly for the first five weeks and then every four weeks up to and including Week 128. In order to maintain the blinding, subjects will receive additional placebo injections at Weeks 17, 18 and 19. All doses of study treatment are administered by sub-cutaneous injections.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>201 subjects will be randomized in a 1:1:1 ratio to secukinumab either 150 mg or 300 mg, or placebo. Subjects on placebo will dose weekly for 5 weeks then once every 4 weeks. At Week 16, ppIGA responders will continue to receive placebo weekly for 5 weeks starting at Week 16, then every 4 weeks up to and including Week 76 while ppIGA non-responders will be randomized in a 1:1 ratio to secukinumab either 150 mg or 300mg weekly for 5 weeks, starting at Week 16, then every 4 weeks up to and including Week 128. At Week 80, subjects on placebo will either terminate their participation, if ppIGA responders, or be randomized in a 1:1 ratio to secukinumab either 150 mg or 300 mg once every 4 weeks until Week 128 inclusive. All doses of study treatment are administered by sub-cutaneous injections.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>secukinumab 150 mg</intervention_name>
    <description>Study treatment will be provided in pre-filled syringes of secukinumab 150 mg in 1 mL. Each dosing consists of one secukinumab 150 mg s.c. injection plus one placebo secukinumab s.c. injection and will take place once weekly during five weeks (at Baseline, Weeks 1, 2, 3 and 4), then once every four weeks starting at Week 8 until Week 128 inclusive. In order to maintain the blinding, patients will also receive two placebo injections at Weeks 17, 18 and 19. Patients will self-administer study treatment under the supervision of site personnel when injections occur during study visits, or at home otherwise.</description>
    <arm_group_label>secukinumab 150mg</arm_group_label>
    <other_name>AIN457 150 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>secukinumab 300 mg</intervention_name>
    <description>Study treatment will be provided in pre-filled syringes of secukinumab 150 mg in 1 mL. Each dosing consists of two secukinumab 150 mg s.c. injections and will take place once weekly during five weeks (at Baseline, Weeks 1, 2, 3 and 4), then once every four weeks starting at Week 8 until Week 128 inclusive. In order to maintain the blinding, patients will also receive two placebo injections at Weeks 17, 18 and 19. Patients will self-administer study treatment under the supervision of site personnel when injections occur during study visits, or at home otherwise.</description>
    <arm_group_label>secukinumab 300 mg</arm_group_label>
    <other_name>AIN457 300 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be provided in 1 mL pre-filled syringes. Each dosing consists of two s.c. injections and will take place once weekly during five weeks (at Baseline, Weeks 1, 2, 3 and 4), then at Week 8 and at Week 12. At Week 16, ppIGA responders will continue on placebo with dosing at Weeks 16, 17, 18, 19 and 20, then once every four weeks from Week 24 until Week 76 inclusive. At Week 80, ppIGA responders will end their participation in the study while ppIGA non-responders will be re-randomized, to receive 150 mg or 300 mg secukinumab once every four weeks starting at Week 80 until Week 128 inclusive. Patients will self-administer study treatment under the supervision of site personnel when injections occur during study visits, or at home otherwise.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with chronic, moderate to severe plaque type psoriasis for at least 6 months
             prior to randomization and significant involvement of the palms and soles at
             baseline, defined as palmoplantar Investigator's Global Assessment (ppIGA) score of ≥
             3 on a 5-point scale, as well as at least one skin plaque at baseline which is not in
             the palmoplantar area

          -  Candidates for systemic therapy, i.e. psoriasis inadequately controlled by topical
             treatment (including super potent topical corticosteroids) and/or phototherapy and/or
             previous systemic therapy

        Exclusion Criteria:

          -  Forms of psoriasis other than chronic plaque type psoriasis (e.g., pustular
             psoriasis, palmoplantar pustulosis, acrodermatitis of Hallopeau, erythrodermic and
             guttate psoriasis)

          -  Drug-induced psoriasis (e.g. new onset or current exacerbation from β-blockers,
             calcium channel inhibitors or lithium)

          -  Ongoing use of prohibited treatments (e.g. topical or systemic corticosteroids (CS),
             UV therapy). Washout periods do apply.

          -  Prior exposure to secukinumab (AIN457) or any other biological drug directly
             targeting IL-17 or the IL-17 receptor

          -  Use of any investigational drugs within 4 weeks prior to study treatment initiation
             or within a period of 5 half-lives of the investigational treatment, whichever is
             longer

          -  Active ongoing inflammatory diseases other than psoriasis that might confound the
             evaluation of the benefit of secukinumab therapy

          -  History of hypersensitivity to constituents of the study treatment

          -  Other protocol-defined inclusion/exclusion criteria do apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40291</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Verona</city>
        <state>New Jersey</state>
        <zip>07044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Goodlettsville</city>
        <state>Tennessee</state>
        <zip>37072-2301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Carlton</city>
        <state>Victoria</state>
        <zip>3053</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2S 3B3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 6L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 3H7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3Z 2S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00250 HUS</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tampere</city>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1134</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miskolc</city>
        <zip>3529</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szeged</city>
        <zip>H-6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Afula</city>
        <zip>1834111</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6209804</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Breda</city>
        <state>CK</state>
        <zip>4818</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stavanger</city>
        <zip>4068</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1998 - 018</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Porto</city>
        <zip>4200-319</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kazan</city>
        <zip>420012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>107076</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>119071</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kosice-Saca</city>
        <state>Slovak republic</state>
        <zip>040 15</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kosice</city>
        <zip>04011</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Svidnik</city>
        <zip>089 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Badalona</city>
        <state>Catalunya</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <state>Las Palmas de G.C</state>
        <zip>35010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ankara</city>
        <zip>06500</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fatih / Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fatih / Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gaziantep</city>
        <zip>27310</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>E11 1NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dudley</city>
        <state>West Midlands</state>
        <zip>DY1 2HQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Finland</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 28, 2017</lastchanged_date>
  <firstreceived_date>January 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Moderate palmoplantar psoriasis</keyword>
  <keyword>Severe palmoplantar psoriasis</keyword>
  <keyword>psoriasis</keyword>
  <keyword>Secukinumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Benzocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
